43 related articles for article (PubMed ID: 38589421)
21. Nav1.6 promotes the progression of human follicular thyroid carcinoma cells via JAK-STAT signaling pathway.
Li H; Liu J; Fan N; Wang H; Thomas AM; Yan Q; Li S; Qin H
Pathol Res Pract; 2022 Aug; 236():153984. PubMed ID: 35753135
[TBL] [Abstract][Full Text] [Related]
22. Identification of Tissue-Specific Expressed Hub Genes and Potential Drugs in Rheumatoid Arthritis Using Bioinformatics Analysis.
Xing X; Xia Q; Gong B; Shen Z; Zhang Y
Front Genet; 2022; 13():855557. PubMed ID: 35368701
[No Abstract] [Full Text] [Related]
23. The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes.
Vuong HG; Le MK; Hassell L; Kondo T; Kakudo K
Head Neck; 2022 Apr; 44(4):926-932. PubMed ID: 35076146
[TBL] [Abstract][Full Text] [Related]
24. 3D modeling in cancer studies.
Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
[TBL] [Abstract][Full Text] [Related]
25. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
26. Extracellular matrix and its therapeutic potential for cancer treatment.
Huang J; Zhang L; Wan D; Zhou L; Zheng S; Lin S; Qiao Y
Signal Transduct Target Ther; 2021 Apr; 6(1):153. PubMed ID: 33888679
[TBL] [Abstract][Full Text] [Related]
27. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
Ptacek J; Hawtin RE; Sun D; Louie B; Evensen E; Mittleman BB; Cesano A; Cavet G; Bingham CO; Cofield SS; Curtis JR; Danila MI; Raman C; Furie RA; Genovese MC; Robinson WH; Levesque MC; Moreland LW; Nigrovic PA; Shadick NA; O'Dell JR; Thiele GM; Clair EWS; Striebich CC; Hale MB; Khalili H; Batliwalla F; Aranow C; Mackay M; Diamond B; Nolan GP; Gregersen PK; Bridges SL
PLoS One; 2021; 16(1):e0244187. PubMed ID: 33444321
[TBL] [Abstract][Full Text] [Related]
28. Tumor microenvironment as a therapeutic target in cancer.
Xiao Y; Yu D
Pharmacol Ther; 2021 May; 221():107753. PubMed ID: 33259885
[TBL] [Abstract][Full Text] [Related]
29. New Therapies for Advanced Thyroid Cancer.
Laha D; Nilubol N; Boufraqech M
Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer.
Chan S; Karamali K; Kolodziejczyk A; Oikonomou G; Watkinson J; Paleri V; Nixon I; Kim D
Eur Thyroid J; 2020 Feb; 9(2):73-84. PubMed ID: 32257956
[TBL] [Abstract][Full Text] [Related]
31. Toll-Like Receptors Signaling in the Tumor Microenvironment.
McCall KD; Muccioli M; Benencia F
Adv Exp Med Biol; 2020; 1223():81-97. PubMed ID: 32030686
[TBL] [Abstract][Full Text] [Related]
32. Thyroid cancer: incidence and mortality trends in China, 2005-2015.
Wang J; Yu F; Shang Y; Ping Z; Liu L
Endocrine; 2020 Apr; 68(1):163-173. PubMed ID: 32002755
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation exploration for ARDS: a multi-omics and multi-microarray interrelated analysis.
Zhang S; Wu Z; Xie J; Yang Y; Wang L; Qiu H
J Transl Med; 2019 Oct; 17(1):345. PubMed ID: 31623626
[TBL] [Abstract][Full Text] [Related]
34. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
35. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
[TBL] [Abstract][Full Text] [Related]
36. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
37. Risk prediction in children and adults less than 45 years old with papillary thyroid cancer.
Konstantinidis A; Tracy E; Sosa JA; Roman SA
Expert Rev Endocrinol Metab; 2017 Sep; 12(5):355-365. PubMed ID: 30058890
[TBL] [Abstract][Full Text] [Related]
38. New Insights in Thyroid Cancer and p53 Family Proteins.
Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
[TBL] [Abstract][Full Text] [Related]
39. Themis2: setting the threshold for B-cell selection.
Deobagkar-Lele M; Anzilotti C; Cornall RJ
Cell Mol Immunol; 2017 Aug; 14(8):643-645. PubMed ID: 28626236
[No Abstract] [Full Text] [Related]
40. ZCCHC12, a novel oncogene in papillary thyroid cancer.
Wang O; Zheng Z; Wang Q; Jin Y; Jin W; Wang Y; Chen E; Zhang X
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1679-1686. PubMed ID: 28424903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
